The term "digital therapeutics" is showing up everywhere in outpatient mental health right now, from payer conversations to clients who've read about it online. But the category isn't one thing. Discussions about digital therapeutics in outpatient mental health often lump together three distinct types of tools, each with a different regulatory status, clinical role, and relationship to the therapist. Getting clear on the differences shapes how you evaluate, recommend, and integrate any digital tool into your practice.
In clinical and regulatory contexts, "digital therapeutics" (DTx) refers to software-based interventions that undergo clinical trials and FDA review. They're a distinct, regulated category, not a synonym for wellness apps. Think of it as a spectrum: FDA-cleared prescription tools at one end, general consumer apps at the other, and clinician-guided AI support tools occupying a meaningful middle ground.
The DTx space has grown quickly. As of early 2026, 12 FDA-cleared or authorized prescription digital therapeutics are available in the U.S., each with a defined clinical scope.
The defining characteristic is FDA clearance backed by clinical evidence. Rejoyn, cleared by the FDA in April 2024, is the first prescription digital therapeutic authorized for major depressive disorder (MDD); it's used as an adjunct to antidepressant medication in clinician-managed outpatient care. DaylightRx, cleared in September 2024, is the first FDA-cleared digital therapeutics mental health tool for generalized anxiety disorder. NightWare, cleared earlier, addresses nightmare disorder and PTSD-related sleep disruption.
These tools treat specific, diagnosed conditions. They require a licensed provider order. That's categorically different from a journaling app or an AI support tool, regardless of how those tools are marketed.
Outpatient mental health has always had a between-session gap. Clients forget what happened during a difficult week, homework adherence is inconsistent, and skill reinforcement depends heavily on what someone does between appointments. Digital tools across the spectrum are designed to address this gap, but the clinical model varies considerably.
Prescription DTx tools function as an adjunct to therapy for specific diagnoses, delivered under a provider's order with defined treatment protocols. Clinician-guided AI support tools reinforce the therapeutic work already in progress, with the therapist shaping what the client engages with between sessions. General wellness apps offer self-directed support with no therapist involvement at all.
It depends on the tool, and that's the issue. With FDA-cleared DTx, the clinician is directly involved: they order the intervention, it's indicated for a specific diagnosis, and it fits into a structured care model. With consumer apps, the clinician's role is effectively zero. Clients use them independently, and the therapist has no context for what's influencing the client between sessions.
The lack of clinician oversight in mental health apps creates a significant blind spot. When clients turn to uncontrolled AI tools on their own, there's no way to know whether what they're engaging with aligns with the treatment plan. The case for clinician-guided outpatient mental health tools is partly about therapeutic alignment and partly about closing that blind spot.
Evaluating any digital tool for clinical use comes down to a few clear questions. Does it align with the therapeutic frameworks you're already using, whether CBT, DBT, IFS, ACT, or mindfulness? Is it a HIPAA-compliant mental health tool with data practices that meet clinical privacy standards? Does it position itself honestly as support, not a replacement for professional care?
The most important question for non-DTx tools is visibility: can you see what your client engaged with between sessions? A mental health app for therapy homework that operates as a black box to the treating clinician offers limited clinical value. Therapeutic reinforcement between sessions only works when the reinforcement stays aligned with what's happening in session.
This distinction is important, and it's worth being direct. Prescription digital therapeutics are FDA-cleared medical devices, indicated for specific diagnoses, delivered under a provider order, and backed by clinical trials. They occupy a defined regulatory lane.
A clinician-guided AI support tool for therapists that is grounded in established therapeutic frameworks occupies a different lane. These tools aren't built to treat a specific condition. They're built to extend between-session mental health support for clients already in therapy. Both have a role in blended care mental health models. They're parallel tracks, not competing ones.
Therapy Ally is a purpose-built clinician-guided AI support tool, not an FDA-cleared digital therapeutic and not a generic wellness app. That positioning is deliberate. Therapists select the Ally that aligns with their therapeutic approach, set guardrails on topics, assign homework that extends session work through the week, configure mood check-ins, and review structured summaries before each appointment.
Therapy Ally is HIPAA compliant. It replaces the blind spot created when clients use uncontrolled AI tools on their own with structured, clinician-guided support that stays aligned with the work in session. Find out more about the Clinician Console at therapyally.ai.